The ever-increasing number of drugs available to treat type 2 diabetes and the complexity of patients with this condition present a constant challenge when it comes to identifying the most appropriate treatment approach. The more recent glucagon-like peptide-1 receptor agonists (GLP-1RAs) are non-insulin injectable options for the management of type 2 diabetes. Effective at improving glycaemic control with a low intrinsic risk of hypoglycaemia and the potential for weight reduction, this agent class is an important addition to the prescribing armamentarium. However, understanding their place in therapy may prove confusing for many primary care practitioners, especially given the common belief that 'injectables' are a last-resort treatment option, which puts them at risk of being niched alongside insulin. This review summarises the clinical evidence for GLP-1RAs and how they compare to other glucose-lowering agents in managing type 2 diabetes. It also provides practical and case-driven opinions and recommendations on the optimal use of GLP1RAs by discussing important patient factors and clinical considerations that will help to identify those who are most likely to benefit from this class of agents. Funding: Eli Lilly Australia.
INTRODUCTION
Despite the availability of an increasing number of agents for treating type 2 diabetes mellitus (T2DM), as many as half of all T2DM patients are failing to meet their glycaemic goals [1] . This paradox may reflect a treatment landscape that appears complex and confusing, making it difficult for practitioners to identify the right drug for the right patient. Moreover, clinical inertia, including a reluctance to use injectable therapies, may also be compromising optimal treatment selection and thus clinical outcomes [2, 3] .
GLP-1RAs are a relatively new class of injectables that are effective at reducing HbA 1c , have a low risk of hypoglycaemia when given as monotherapy or in the absence of sulphonylureas (SU) or insulin, and have the potential for weight loss-key considerations when treating a typical obese patient with T2DM [4] . In addition, individual GLP-1RAs have been developed to overcome common barriers to self-injection by offering a lower injection burden (i.e. weekly vs. daily injections) and devices with a 'hidden' pre-attached needle (e.g. dulaglutide) [5, 6] .
Nonetheless, current clinical practice in managing T2DM using GLP-1RAs is likely to vary worldwide due to differences in healthcare systems and their accessibility, in the availability and affordability of medications, as well as in country-specific reimbursement policies. For instance, Australia differs to other regions (such as the USA) where patients are responsible for almost all of their healthcare costs in having a publicly funded healthcare insurance system that provides a rebate for doctor and specialist visits, blood tests and X-rays, although it should be noted that the rebate does not always cover the full cost of medical services, and patients incur 'out-of-pocket' expenses. Also, Australia, the USA and the UK differ in the GLP-1RAs that have received regulatory approval. Among those currently available in Australia, not all are eligible for government reimbursement. Adding to the complexity are the criteria for a subsidised GLP-1RA, which can limit the choice of additional or add-on therapies; e.g. at present, the government will not subsidise a GLP-1RA if given with an insulin. This therefore affects the prescribing patterns of GLP-1RAs in Australia.
In other regions, e.g. Asia or the Middle East, access to and the use of GLP1-RAs are primarily driven by whether the patient can afford it.
Five GLP-1RAs are available in Australia (dulaglutide, exenatide BD, exenatide QW, liraglutide, and lixisenatide), one is undergoing regulatory approval (semaglutide), and three are currently available under the government's reimbursement scheme (dulaglutide, exenatide BD, and exenatide QW). The aim of this article is to explore their clinical rationale, assess where they fit in the current guideline approach and identify which patients may derive benefit from their use. This will allow practitioners to be better informed about why, when and how to treat T2DM with GLP-1RAs appropriately. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.
CLINICAL RATIONALE FOR GLP-1RAS IN T2DM
It is well recognised that T2DM is a complex and multifactorial disorder attributable to the eight underlying pathophysiological defects labelled the 'ominous octet' [7] . Involving multiple organs, these abnormalities collectively drive the clinical manifestation of the disease (i.e. hyperglycaemia) [7] . The importance of targeting the underlying pathophysiology of T2DM rather than focusing management on reducing plasma glucose levels, as is currently recommended, has recently been debated [8] . It was argued that therapeutic guidelines fail to achieve sustained HbA 1c reductions and therefore treatment should be based on addressing pathophysiological defects [8] . In this context, GLP-1RAs are able to target six of these biological abnormalities, whereas other agents such as metformin target mainly one (Fig. 1) [7, 8] .
Fundamentally, GLP-1RAs work by stimulating insulin secretion and inhibiting glucagon secretion in a glucose-dependent manner [9] , which explains their associated low risk of hypoglycaemia. Importantly, GLP-1RAs are able to improve b-cell sensitivity to glucose and have the ability to improve the glycaemic profile indirectly by delaying gastric emptying, inhibiting hepatic glucose production and suppressing appetite, thereby promoting weight loss [9] [10] [11] .
GUIDELINE RECOMMENDATIONS ON GLP-1RAS
When and Where Do GLP-1RAs Fit into Current Management?
As different classes of drugs target different aspects of T2DM via distinct mechanisms of action, a combination of treatments is generally more effective at maintaining glycaemic control than monotherapy over the long term [12] . Indeed, Australian guidelines recommend GLP1RAs as an add-on option to metformin from the second-line setting (Fig. 2) [13, 14], dispelling the common notion that injectable therapies are a 'last resort' or restricted only to those individuals who fail to respond to maximal doses of oral agents. These guidelines, however, do not give a preference regarding which of the second-line agentswhich also include sulfonylureas (SU), dipeptidyl peptidase-4 inhibitors (DPP-IV), sodiumglucose cotransporter 2 inhibitors (SGLT-2i), insulin, thiazolidinediones (TZD) and acarbose-should be added to optimised metformin [13, 14] 2 ), which have increased since his last review a year ago. He is receiving a maximal daily dose of metformin extended release (2000 mg; nocte). He also has a history of hypertension and dyslipidaemia that are being successfully managed with amlodipine, low-dose aspirin and atorvastatin. He works in construction in a hot environment.
Suboptimal glycaemic control and increasing weight gain-major risk factors for blood glucose and CV complications-are key concerns for this patient. How would the addition of a GLP-1RA compare to other second-line add-on therapies in improving management of the T2DM?
A review of head-to-head clinical trials comparing key outcomes of using GLP-1RAs (dulaglutide, exenatide BD, exenatide QW, liraglutide or lixisenatide) with those of using DPP-IV (sitagliptin), SU (glimepiride; glibenclamide), TZD (rosiglitazone; pioglitazone) and Table A below [25] . Note, no head-tohead studies of GLP-1RAs and SGLT-2 inhibitors or acarbose are available.
Given that there are few head-to-head studies comparing glucose-lowering effects between different drug classes, and the difficulty involved in performing cross-study comparisons due to different patient characteristics and [41, 42] , a more recent meta-analysis reported that long-acting, onceweekly GLP-1RAs (exenatide and dulaglutide) achieve significantly greater reductions in HbA 1c than basal insulins such as insulin detemir, insulin glargine and insulin degludec [43] . However, insulin was found to be more effective at reducing fasting plasma glucose but less effective at reducing postprandial glucose levels than GLP-1RAs [42, 44] . Several systematic reviews also indicated that GLP-1RAs are consistently effective at reducing body weight [25, 41, 42, 44] , supporting the nonglycaemic role of this agent class [44] , as opposed to the weight gain that commonly accompanies insulin treatment [44] . Furthermore, the risk of hypoglycaemia-a major challenge when using insulin-is reportedly lower with GLP-1RAs, given their glucose-dependent mechanism of modulating insulin release and glucagon suppression [25] . Alongside these benefits of GLP1RAs, however, is an increased propensity for GI adverse events, notably nausea, when compared with insulin. Table 1 outlines these comparisons further.
Given that weight control and a low risk of hypoglycaemia are key considerations for this patient, the addition of a GLP-1RA may be the most appropriate choice. This selection is further supported by the CV outcomes data for specific GLP-1RAs, which point to benefits in reducing the risk of MACE in at-risk individuals [16] [17] [18] . The most appropriate GLP-1RA to use will ultimately be dictated by the device and how it aligns with the patient's needs, as well as associated costs and the reimbursement status of the drug options. GLP-1RAs can also be differentiated according to their duration of receptor activation. Short-acting agents undergo renal clearance, so they require once-daily (lixisenatide) or twicedaily (exenatide BD) dosing. Long-acting agents, on the other hand, provide continuous receptor activation due to structural modifications that slow their absorption, reduce the rate of renal clearance or extend their half-lives [52, 53] . These GLP-1RAs include once-weekly dulaglutide, exenatide and semaglutide (yet to be approved in Australia) and once-daily liraglutide (Table 2) . Differences in the duration of action may also account for their differential effects on fasting and postprandial glucose [54] . For instance, short-acting GLP-1RAs are more strongly associated with delayed gastric emptying than long-acting agents, leading to a greater impact on postprandial glucose. In contrast, the persistent effects of longer-acting GLP-1RAs offer 24-h glucose control, including fasting glucose [53] . As a result, patients with largely postprandial hyperglycaemia are more likely to benefit from treatment with short-acting GLP1-RAs as opposed to individuals with predominantly fasting hyperglycaemia, who would derive greater benefit from long-acting agents [52] .
In terms of tolerability, GLP-1RAs are commonly associated with GI side effects, which are often dose-dependent and time-limiting [55] . However, long-acting GLP-1 RAs appear to cause less nausea and vomiting but more diarrhoea than short-acting agents [56] . The frequency of these events is lower with onceweekly GLP-1RAs compared to once-daily or twice-daily GLP-1RAs (Table 2 ) [57] . Of note, a small number of cases of acute pancreatitis associated with GLP-1RA use have been reported in clinical trials: 38 cases in 17,775 patientyears of exposure compared with 9 events in 5863 patient-years of exposure with the comparator treatment. Resulting pooled event rates were 2.1 and 1.5 per 1000 patient-years of exposure, respectively, and the OR was 1.39 (95% CI 0.67, 2.88), suggesting a slightly elevated risk [58] . In a separate meta-analysis, a significantly increased risk of cholelithiasis (OR 1.30; 95% CI 1.01-1.68; p = 0.041) but not pancreatitis or pancreatic cancer was reported for GLP-1RAs compared with comparator treatments [59] . A more recent analysis using cardiovascular outcome trials further indicated no excess risk of either acute pancreatitis [Peto OR 0.89 (95% CI 0.63, 1.27)] or pancreatic cancer [Peto OR 0.84 (95% CI 0.53, 1.35)] with GLP1RAs vs. placebo when added to the standard of care [60] . An increased risk of diabetic retinopathy has been reported in a clinical trial of semaglutide, which has been hypothesised to be related to the magnitude and rapidity of [61] ; this complication does not appear to be a class-driven effect.
Tackling Adherence Challenges One GLP-1RA at a Time T2DM management has shifted from a 'one size fits all' approach to a more holistic, patientcentred approach that aligns goals of management, such as glycaemic targets and risk factor control (e.g. weight or CV risk), with patient preferences and characteristics [62] . Involving the patient in treatment decisions also helps with adherence to therapy, which is a major challenge in T2DM. For instance, in an Australian study, approximately a third of patients with T2DM were found to have suboptimal adherence to their diabetes medication [63] .
Strategies that address convenience in terms of simplicity of drug regimens, formulations and delivery devices have been shown to improve adherence [64] . Indeed, GLP-1RAs have evolved over time such that the frequency of dosing has decreased from twice-daily (exenatide, BD) [65] , to once-daily (liraglutide, lixisenatide) [66, 67] to once-weekly (dulaglutide, exenatide QW, semaglutide) [5, 6] , suggesting a higher adherence potential for the longer-acting agents (Table 2) . Moreover, improvements in drug formulations (such as those which do not require reconstitution or dose titration) and injection devices with hidden and pre-attached needles, which together serve to reduce treatment complexity, may lead to a more positive injection experience for patients (Table 3 ) [68] .
Indeed, lowering the regimen complexity and treatment burden has been shown to improve treatment satisfaction, which in turn plays an important role in supporting adherence to medication [69] . Data on patient-reported outcomes for individual GLP-1RAs indicate high treatment satisfaction rates with the long-acting agents (Table 3 ) [69] [70] [71] [72] [73] [74] , while dulaglutide was associated with higher adherence and persistence rates than exenatide QW and liraglutide [75] . Given the many factors that come into play when deciding on the most appropriate choice of treatment for T2DM in an individual patient, in the context of GLP-1RAs, a clinical decision algorithm that incorporates author opinion is proposed; see Fig. 3 [5, 6, 24, 50] .
Practical Considerations for GLP-1RA Use
As GLP-1RAs are injectables, comparisons of GLP1RAs with insulins are inevitable. However, the practicalities of initiating GLP-1RAs are far less complicated, largely due to the simpler injection devices involved. For those patients who express concerns about injections or lack confidence with self-injections, it would be appropriate for the primary practitioner to demonstrate the ease with which these devices can be used. If needle phobia is a particular issue, discussion of options that have the needle hidden and/or have a preattached needle, which require minimal handling by the patient, could be considered.
While most GI side effects (nausea, vomiting and diarrhoea) caused by GLP-1RAs are mild to moderate and short-lived [5, 6, 50] , they can be minimised by recommending simple measures such as eating smaller meals, stopping eating as soon as the patient feels full, and injecting at mealtimes. Some GLP-1RAs devices have the ability to easily adjust the dose in response to intolerance (e.g. the liraglutide pen allows for a 0.6-mg dose adjustment) [66, 76] .
Diabetes educators and/or practice nurses with a specialty in diabetes are an important point of contact for patient education; such services are particularly valuable to primary practitioners who are time-constrained.
CONCLUSIONS
GLP-1RAs are effective at improving glycaemic control and, by virtue of their mechanism of action, have a low risk of hypoglycaemia combined with the potential for weight loss. Considering that many patients with T2DM are obese, these agents represent important options among the current therapeutic arsenal. From a practical point of view, different GLP-1RAs offer different dosing and device experiences, allowing practitioners to tailor treatment according to the needs of the individual patient. 
ACKNOWLEDGEMENTS
Funding. This review and the article processing charges were funded by Eli Lilly Australia. All authors had full access to the articles reviewed in this manuscript and take complete responsibility for the integrity and accuracy of this manuscript.
Medical Writing Assistance. Editorial assistance in the preparation of this article was provided by Dr. Beejal Vyas-Price of McCann Healthcare, Australia. Support for this assistance was funded by Eli Lilly Australia.
Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Compliance with Ethics Guidelines. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.
Data Availability. Data sharing is not applicable to this article as no datasets were generated or analysed during the current study. 
